Blood cancer patients who receive a type of anti-cancer therapy should continue to take the drug while having COVID-19 ...

A study of 200 patients with chronic lymphocytic leukemia (CLL) showed a lower rate of severe and serious adverse events ...

Munich news, health insurance, technology, jobs and other topics for expatriates. The Eye Newspapers covers daily news and offers services for foreigners.

Evidence shows pausing BTKi therapy for COVID-19 vaccination does not affect antibody responses to the vaccine ...

CLL/SLL是一种成熟B淋巴细胞克隆增殖性肿瘤，以淋巴细胞在外周血、骨髓、脾脏和淋巴结聚集为特征，也是西方成人中最常见的白血病类型2。欧美人群中年发病率达到（4-5）/10万，亚洲人群的发病率则是欧美的1/10。欧美中位发病年龄在70-75岁，而中 ...

Blood samples from islanders with certain types of cancer will be used in a pioneering piece of research being conducted at ...

In just over a year since its US Food and Drug Administration (FDA) approval, pirtobrutinib (Jayprica) has become a standard ...

Researchers have revealed a new finding that could improve cancer care immunotherapy treatments, particularly for CLL and ...

The IMPROVE study investigated whether a three-week pause in BTKi therapy around the time of COVID-19 vaccination would improve the antibody response in patients with CLL, compared to continuing ...

Blood cancer patients who receive a type of anti-cancer therapy should continue to take the drug while having COVID-19 vaccinations, a new study ...

Minimal residual disease negativity was achieved at a significantly higher rate with venetoclax-based therapies, supporting its role in CLL.

During a Case-Based Roundtable® event, John N. Allan, MD, discussed how new regimens using BTK inhibitors and venetoclax ...